XATRAL

This brand name is authorized in Austria, Australia, Brazil, Canada, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong, Ireland, Israel, Italy, Lithuania, Malta, Mexico, Netherlands, Romania, Singapore, Tunisia, Turkey, United Kingdom, South Africa

Active ingredients

The drug XATRAL contains one active pharmaceutical ingredient (API):

1 Alfuzosin UNII 75046A1XTN - ALFUZOSIN HYDROCHLORIDE

Alfuzosin is an orally active quinazoline derivative. It is a selective, peripherally acting antagonist of postsynaptic alpha-1-adrenoceptors. In vitro pharmacological studies have documented the selectivity of alfuzosin for the alpha-1-adrenoreceptors located in the prostate, bladder base and prostatic urethra. Read about Alfuzosin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
XATRAL XL Prolonged release tablets	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
G04CA01	Alfuzosin	G Genito urinary system and sex hormones → G04 Urologicals → G04C Drugs used in benign prostatic hypertrophy → G04CA Alpha-adrenoreceptor antagonists
Discover more medicines within G04CA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 4277D
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 576720090086817
Country: CA	Health Products and Food Branch	Identifier(s): 02245565
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 29579-1-01-11
Country: EE	Ravimiamet	Identifier(s): 1011632, 1064247, 1529557, 1529568
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 566042, 566075
Country: FR	Base de données publique des médicaments	Identifier(s): 60443609, 61889938, 62415971, 64068708
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 139798, 139800, 175984, 31878, 31888
Country: HK	Department of Health Drug Office	Identifier(s): 41468, 47335
Country: IE	Health Products Regulatory Authority	Identifier(s): 52613, 52751, 53406, 53572, 53597
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 3643, 4360
Country: IT	Agenzia del Farmaco	Identifier(s): 027314044
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1003208, 1003439, 1014150
Country: MT	Medicines Authority	Identifier(s): AA908/18301, MA1359/03501, PI1438/02201A, PI908/18302A
Country: MX	Comisión Federal para la Protección contra Riesgos Sanitarios	Identifier(s): 534M2000
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 54798
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W62086002, W62086003
Country: SG	Health Sciences Authority	Identifier(s): 09546P, 11579P
Country: TN	Direction de la Pharmacie et du Médicament	Identifier(s): 6453041, 6453043
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8699809037748
Country: ZA	Health Products Regulatory Authority	Identifier(s): 35/5.2/0074